The Role Rapid Acceleration of Diagnostics Tech Continues to Play in the Covid-19 Pandemic and Next Steps - CIMIT MAIN

Accelerating HealthTech Innovation

CIMIT is a trusted partner to organizations investing in medical innovation by providing efficient processes, leading market expertise and resources that enable economic progress and improved healthcare outcomes.

Learn More

We are thrilled to announce that we’ve been selected as one of the first spokes of the ARPA-H Investor Catalyst Hub network!

We are excited to be a part of this nationwide network dedicated to accelerating groundbreaking advances in science and medicine—all in pursuit of better health outcomes for everyone.

Learn more >

Funding Opportunities and Events

NIH Rapid Acceleration of Diagnostics Technology (RADx® Tech) Fetal Monitoring Challenge

$2 million in prizes to accelerate the development of diagnostic and monitoring technologies to reduce the risk of fetal morbidity and mortality and thus improve fetal and neonatal health outcomes.

Research and Innovation Translation Partnerships in Point-of-Care Technologies Conference and Technology Showcase

A two-day conference with researchers, technology developers, clinicians, and industry partners.

Center for Innovative NeuroTech Advancement

News and Annoucements

null The Role Rapid Acceleration of Diagnostics Tech Continues to Play in the Covid-19 Pandemic and Next Steps

Tracy E McMahon

Modified 6 Months ago.

The Role Rapid Acceleration of Diagnostics Tech Continues to Play in the Covid-19 Pandemic and Next Steps

Rapid Acceleration of Diagnostics (RADx) Tech is a National Institutes of Health (NIH)-funded program launched on 29 April 2020, to accelerate commercialization of novel lab-based, point-of-care, and home-based tests to diagnose infection with SARS-CoV-2, the virus that causes COVID-19. RADx Tech was implemented and coordinated by the Consortia for Improving Medicine with Innovation & Technology (CIMIT) in its role as the Coordinating Center for the Point-of-Care Technologies Research Network (POCTRN) in conjunction with the NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the four POCTRN Centers.

Read the full article in the Expert Review of Molecular Diagnostics >

Connect with Us

JOIN OUR EMAIL LIST

Our Lasting Impact

As an early pioneer in managing translational research, CIMIT has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.